Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia, First-in-human, Clinical Study of the Safety, Tolerability, and Pharmacokinetics of H1710 for Injection in Participants With Advanced Solid Tumors

NCT06992713 is registered in ClinicalTrials.gov with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT06992713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06992713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia, First-in-human, Clinical Study of the Safety, Tolerability, and Pharmacokinetics of H1710 for Injection in Participants With Advanced Solid Tumors
Lead sponsor
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
June 18, 2025
Completion date
November 30, 2026
Enrollment
36 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor